- Active Pharmaceutical Ingredients
- 酒石酸伐尼克兰
- Aprepitant, Fosapitant Intermediates
- 福沙匹坦双葡甲胺
- 维格列汀
- 艾氟康唑
- Luliconazole Intermediate
- 钆特酸葡胺
- Succinyl Alcohol Intermediate
- Mirabillon Intermediate
- Atazanavir Intermediate
- Intermediate
- 酒石酸伐尼克兰
- 阿瑞匹坦 287930-73-8
- 阿瑞匹坦 127852-28-2
- 阿瑞匹坦 287930-75-0
- 阿瑞匹坦 200000-59-5
- 阿瑞匹坦 155742-64-6
- 阿瑞匹坦 252742-72-6
- 福沙匹坦双葡甲胺 990-91-0
- 福沙匹坦双葡甲胺 265121-01-5
- 维格列汀 207557-35-5
- 维格列汀 702-82-9
- 艾氟康唑 144230-50-2
- 艾氟康唑 133775-25-4
- 艾氟康唑 127000-90-2
- 钆特酸葡胺
- 米拉贝隆
- 卢立康唑 98873-55-3
- 卢立康唑 126534-31-4
- 硫酸阿扎那韦
- 硼替佐米 179324-87-9
- 硼替佐米 114457-94-2
- 硼替佐米 205393-22-2
- 布林佐胺
- 利伐沙 446292-08-6
- 利伐沙 446292-07-5
- 西那卡塞 1005450-55-4
- 西那卡塞 585-50-2
- Eletriptan Intermediate
- 茚达特罗 312753-53-0
- 茚达特罗 173140-90-4
- Sitagliptin Intermediate
- Fosanavir Calcium Intermediate
Popular information
Bortezomib pinanediol ester
【Catalogue Number】AP0102
【CAS #】205393-22-2
【Molecular formula】 C29H39BN4O4
【Introduction】Bortezomib pinanediol ester, the English name is Bortezomib-Pinanediol, the American Chemical Abstracts Registry number is cas 205393-22-2.
Bortezomib pinanediol ester
CAS 205393-22-2
Other name Butezomipine diol
Catalog number AP0102
CAS # 205393-22-2
Molecular formula C29H39BN4O4
Molecular weight 518.46
Structural formula
Product introduction
CAS 205393-22-2 Bortezomib alkyl diol ester, English name is Bortezomib-Pinanediol, American Chemical Abstracts Registration Number is cas 205393-22-2.
Bortezomib oxanediol ester (cas 205393-22-2) is an intermediate of bortezomib. Bortezomib is a reversible inhibitor of 26S proteasome chymotrypsin-like activity in mammalian cells. Proteolysis can affect the cascade of multilevel signals in the cell, and this damage to the normal intracellular environment can lead to cell death. Inhibition of the 26S proteasome prevents hydrolysis of specific proteins. In vitro tests have proven that bortezomib is cytotoxic to many types of cancer cells. Preclinical tumor model in vivo tests have demonstrated that bortezomib can delay tumor growth, including multiple myeloma. Bortezomib can be used in the treatment of patients with multiple myeloma.
VIWIT 沪ICP备12014533号-1
